CRISPR Therapeutics AG

DB:1CG Stock Report

Market Cap: €2.8b

CRISPR Therapeutics Valuation

Is 1CG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1CG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€142.59
Fair Value
76.0% undervalued intrinsic discount
24
Number of Analysts

Below Fair Value: 1CG (€34.2) is trading below our estimate of fair value (€142.59)

Significantly Below Fair Value: 1CG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1CG?

Key metric: As 1CG barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1CG. This is calculated by dividing 1CG's market cap by their current book value.
What is 1CG's PB Ratio?
PB Ratio1.7x
BookUS$1.93b
Market CapUS$3.08b

Price to Book Ratio vs Peers

How does 1CG's PB Ratio compare to its peers?

The above table shows the PB ratio for 1CG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.5x
BIO3 Biotest
2.2xn/a€1.4b
FYB Formycon
0.9x77.62%€429.1m
HPHA Heidelberg Pharma
5.9x-14.02%€148.2m
1SXP SCHOTT Pharma KGaA
4.8x14.81%€4.0b
1CG CRISPR Therapeutics
1.7x43.13%€3.1b

Price-To-Book vs Peers: 1CG is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (3.5x).

Price to Book Ratio vs Industry

How does 1CG's PB Ratio compare vs other companies in the DE Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.21m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1CG 1.7xIndustry Avg. 2.6xNo. of Companies4PB00.61.21.82.43+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1CG is good value based on its Price-To-Book Ratio (1.7x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is 1CG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1CG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1CG's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1CG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€34.20
€72.79
+112.84%
56.63%€238.14€28.44n/a24
May ’26n/a
€71.53
0%
56.28%€235.33€28.10n/a24
Apr ’26n/a
€78.83
0%
53.14%€248.41€29.66n/a24
Mar ’26n/a
€79.88
0%
53.64%€256.07€30.58n/a25
Feb ’26n/a
€79.61
0%
54.48%€255.51€28.60n/a24
Jan ’26n/a
€78.03
0%
41.60%€189.95€28.64n/a24
Dec ’25n/a
€78.03
0%
41.60%€189.95€28.64n/a24
Nov ’25n/a
€75.77
0%
41.63%€181.31€27.33n/a24
Oct ’25n/a
€75.90
0%
41.21%€180.97€27.28n/a24
Sep ’25n/a
€75.90
0%
41.21%€180.97€27.28n/a24
Aug ’25n/a
€79.97
0%
39.98%€183.90€27.72n/a24
Jul ’25n/a
€79.97
0%
39.98%€183.90€27.72n/a24
Jun ’25n/a
€79.97
0%
39.98%€183.90€27.72n/a24
May ’25n/a
€82.79
0%
39.01%€186.96€28.19n/a24
Apr ’25n/a
€81.07
0%
39.03%€183.16€27.61n/a24
Mar ’25n/a
€80.67
0%
39.34%€183.90€27.72n/a24
Feb ’25n/a
€80.25
0%
44.12%€183.74€27.70n/a24
Jan ’25n/a
€78.04
0%
43.25%€171.27€27.33n/a25
Dec ’24n/a
€82.56
0%
48.70%€205.57€39.24n/a24
Nov ’24n/a
€83.93
0%
48.11%€208.19€40.69n/a24
Oct ’24n/a
€82.23
0%
44.96%€209.42€40.93n/a25
Sep ’24n/a
€79.42
0%
47.95%€201.76€39.44n/a26
Aug ’24n/a
€76.57
0%
45.15%€198.31€37.86n/a27
Jul ’24n/a
€78.90
0%
45.49%€204.78€39.09n/a27
Jun ’24n/a
€78.69
0%
45.39%€204.47€39.03n/a27
May ’24n/a
€77.50
0%
46.86%€199.65€35.39n/a25
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
€74.53
Fair Value
54.1% undervalued intrinsic discount
24
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 05:24
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 44 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research